# To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

> **NCT01223898** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Tasigna

## Key facts

- **NCT ID:** NCT01223898
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01223898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01223898, "To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01223898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*